EAU 2013 - Programme Book - YouMed

Sunday
Sunday, 17 March - EAU Programme
164 Programme Book
Thematic Session 3
11.00 - 12.00 From bench to bedside: What will be replacing PSA?
Blue Hall 1-2 - Level N1
Chair: Z. Culig, Innsbruck (AT)
11.00 - 11.15 State-of-the-art lecture Gene fusions in prostate cancer: Is it helping?
T. Visakorpi, Tampere (FI)
Aims and objectives
The finding of TMPRSS2:ERG fusion immediately raised the question could it be utilized in the treatment of
prostate cancer, either as a drug target or as a biomarker. What is good about the fusion genes as biomarkers,
is that they are genetic alterations. As such they are cancer specific and do not exist in normal cells. There
has been a large number of publications interrogating whether the TMPRSS2:ERG fusion detected in tissue
specimen is associated with prognosis. Most of the studies suggest it is not. There have also been a few
studies detecting the fusion from blood, circulating tumor cells (CTCs), and urine. And, it seems that in a
combination with PCA3, TMPRSS2:ERG could improve the utility of serum PSA to detect clinically significant
cancer. Also other fusion genes than TMPRSS2:ERG have been and will be identified in prostate cancer.
Common factor for these fusions is that they are rare. Thus, they will unlikely have a potential of being
biomarkers alone. However, they may turn out to be useful in selecting targeted drugs if available.
11.15 - 11.30 State-of-the-art lecture The role of the pathologist in clinical prognosis
G. Kristiansen, Bonn (DE)
11.30 - 11.45 State-of-the-art lecture MicroRNA in prostate cancer diagnosis
H. Sültmann, Heidelberg (DE)
Aims and objectives
miRNAs are small non-coding RNAs involved in posttranscriptional regulation of gene expression. While
recent studies have suggested the usefulness of miRNAs in tissues and body fluids for tumor diagnosis,
prognosis, and prediction, technical parameters, e.g. nucleic acid recovery from limited sources of
biomaterial, sample standardisation, data normalisation, as well as independent validation of screening
data, are still challenging. The presentation will highlight the potential as well as obstacles for translating
miRNA markers into diagnostic applications for prostate cancer.
11.45 - 12.00 Abstract presentations: Special selection from the poster sessions
1045 Urinary PCA3 and TMPRSS2:ERG help predict biopsy outcome prior to initial prostate biopsy using a risk
group analysis
J.R. Day, L.A. Jones, S.E. Meyer, P.N. Hodge, J. Aussie, D.R. Saltzstein, J.C. Groskopf (San Diego, San Antonio,
United States of America)
139 Reducing unnecessary biopsies for suspicion of prostate cancer: Extension and validation of an ERSPC
based risk calculator with Phi
M.J. Roobol, D. Nieboer, A. Houlgatte, S. Vincendeau, M. Lazzeri, G. Guazzoni, C. Stephan, A. Semjonow,
A. Haese, M. Graefen, E.W. Steyerberg (Rotterdam, The Netherlands; Paris, Rennes, France; Milan, Italy;
Berlin, Munster, Hamburg, Germany)